news
Shire’s Alagille syndrome drug, SHP625, fails in Phase II trial
9 April 2015 | By Victoria White
Shire has announced that the Phase 2 IMAGO trial of its investigational compound SHP625 did not meet the primary or secondary endpoints...
List view / Grid view
Shire
news
Shire announces clear regulatory path forward for SHP465, an investigational treatment for adults with ADHD
7 April 2015 | By Victoria White
Shire has announced a clear regulatory path for SHP465, an investigational medication being evaluated as a potential treatment for ADHD in adults...
news
Shire (SHP LN): Pipeline to deliver 2015 catalysts; PT +17% to 5500p
20 January 2015 | By Edelman
We believe NPS is a solid acquisition and are confident management can extract significant Revenue and operating synergies, with focus on the 24 Jan FDA action on Natpara...
news
Shire completes ‘robust’ deal in $5.2 billion NPS Pharmaceuticals acquisition, says GlobalData Analyst
16 January 2015 | By GlobalData
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData...
news
Shire submits INTUNIV® (guanfacine extended release) Marketing Authorisation Application to EMA
1 April 2014 | By Shire
Shire plc announced the acceptance of submission of a Marketing Authorisation Application by the European Medicines Agency for their once-daily, non-stimulant guanfacine extended release...
news
Shire’s VPRIV® wins first ever “Novel Treatment Award”
19 February 2013 | By Edelman on behalf of Shire
"Shire has demonstrated its commitment to developing new therapies for the treatment of rare genetic diseases..."
news
Shire plc becomes OBN’s first Corporate Patron
23 September 2010 | By Citigate Dewe Rogerson
OBN, announced today that global specialty pharmaceutical company Shire has become the network’s first Corporate Patron...
